Sign in Subscribe
Vaccination

mRNA Vaccines and Antiviral Pills: The New Leaders in the Fight Against COVID-19

Strategic Insights

— 1 min read

In the wake of the Omicron variant, mRNA vaccine makers like Moderna and BioNTech have seen their stocks rise significantly, as investors pin their hopes on these adaptable technologies. Key to their success is the genetic code wrapped in tiny bubbles of fat, allowing for rapid development of new versions in response to evolving threats. This adaptability, combined with the emergence of effective antiviral pills like Pfizer's Paxlovid, positions mRNA vaccines and antiviral treatments as the frontlines in the fight against COVID-19.

Key Takeaways:

  • Moderna's shares have risen by a third, with BioNTech's shares not far behind, in response to the Omicron variant.
  • mRNA vaccines can be adapted to new variants in as little as 100 days, compared to traditional vaccines which may take longer to update.
  • The National Institutes of Health's director suggests that a third dose of existing vaccines may be sufficient to counter the Omicron variant.
  • Booster programmes will solidify the position of mRNA vaccine makers like Moderna and BioNTech.
  • Pfizer and BioNTech dominate the market, with Pfizer expecting to rake in $36bn in revenue this year, and four-fifths of that next year.
  • The antiviral pill, Paxlovid, slashes hospitalisation risk by a greater degree than a similar drug from Merck, with both companies expected to price their drugs at about $700 for a course of treatment.
  • Analysts predict that Pfizer's revenue could top $100bn in 2022, a record for the pharma industry.

Statistics:

  • Moderna's shares have risen by a third.
  • mRNA vaccines can be adapted to new variants in as little as 100 days.
  • Pfizer's revenue forecast for this year is $36bn.
  • Pfizer will rake in four-fifths of its revenue from vaccine sales next year.
  • Paxlovid slashes hospitalisation risk by a greater degree than Merck's similar drug.
  • Analysts predict that Pfizer's revenue could top $100bn in 2022.

Sources:

  • [Moderna's stock rise (no specific date mentioned)]
  • [BioNTech's stock rise (no specific date mentioned)]
  • [National Institutes of Health's director's statement on Omicron (no specific date mentioned)]
  • [Pfizer's forecast for $36bn revenue (no specific date mentioned)]
  • [Merck's antiviral pill's effectiveness (no specific date mentioned)]

Read more